Drug details

Erbitux (cetuximab)

type of Antineoplastics Monoclonal Antibody, Antineoplastics EGFR Inhibitors

Erbitux (cetuximab), in combination with radiation therapy, is a monoclonal antibody indicated for the initial treatment of locally or regionally advanced head and neck cancer of a specific type (squamous cell carcinoma). Used alone, Erbitux is also approved to treat patients with head and neck cancers that have returned in the same location or spread to other parts of the body and for head and neck cancers that have progressed following platinum-based chemotherapy. Erbitux is also used on metastatic colorectal cancers that contain epidermal growth factor receptors.

This drug may have the following side effects:

• nausea,
• headache,
• vomiting,
• diarrhea,
• itching,
• weight loss,
• upset stomach,
• rash,
• dry or cracked skin,
• nail changes,
• weakness, and
• respiratory, skin, and mouth infections.

The following drugs are related to Erbitux, either as a replacement or used together:

• Adrucil (fluorouracil injection)
• Sancuso (granisetron transdermal system)
• Udenyca (pegfilgrastim-cbqv injection)
• Turalio (pexidartinib capsules)